BLTE
Belite Bio, Inc
NASDAQ · Healthcare · Biotechnology · US
$193.61
+13.16%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -79.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +94.4%
- EPS
- +61.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- -95.8%
- Free cash flow
- -26.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026